Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?

By Y. Shaib, J. Davila, K. McGlynn, H. B. EL‐SERAG. Journal of Hepatology, 2004

678 citations recorded by the source corpus.

Subfields: Hepatology, Pulmonary and Respiratory Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/931c2e0549c322292f4ef139bf0505fabd4b41bc

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hepatology

1. Peter R. Galle
2. G. Gores
3. J. Llovet
4. Jordi Bruix1 , 2
5. Riccardo Lencioni

In Pulmonary and Respiratory Medicine

1. G. Gores

In Surgery

1. J. Llovet
2. G. Gores

Citations in the corpus

• Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. (2014, background): “iCCA incidence increased by 165%, during which time no significant changes were found in the proportion of patients with unstaged cancer, localized cancer, microscopic confirmation, or with tumor size <5 cm, suggesting a true increase in iCCA rather than earlier or improved diagnosis [10,11].”
• Cholangiocarcinoma — evolving concepts and therapeutic strategies (2017, neutral): “…of pCCA is not always possible, often necessitating a diagnosis based on clin­ ical criteria (for example, a mass lesion and malignant­ appearing stricture with elevated serum CA 19–9 levels); the major differential diagnosis for a perihilar stricture is pCCA versus IgG4 cholangiopathy 59 .”